Granted Patent
B2
US 12,465,589 · App. 18/301,099 · Granted Nov 11, 2025
Method and composition for treating CNS disorders
Inventors:
Ramachandra Mukunda (Potomac, MD); Jagadeesh S. Rao (Ashburn, VA); Amar R. Mukunda (Bethesda, MD)
Assignee:
IGC Pharma IP, LLC
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Compositions and methods for treating a range of Central Nervous System (CNS) disorders and diseases such as amyloidosis, protein folding diseases, tauopathy, and specifically Alzheimer's Disease and Parkinson's Disease, among others, in humans and in veterinary animals, by administering to a subject in need thereof a formulation comprising of melatonin, curcumin, and cannabis , specifically THC alone or with CBD.
Claims (19)
1 . Composition for treating symptoms of Alzheimer's disease; the composition comprising:
(i) tetrahydrocannabinol (THC) in a dose amount per 70 kg patient from 1.0 mg to 3.0 mg,
(ii) melatonin in a dose amount per 70 kg patient from about 14 μg to about 77.0 mg, and
(iii) curcumin in a dose amount per 70 kg patient from about 0.35 mg up to 0.5 mg.
2 . Composition of claim 1 which is a 1 mL oral suspension.
3 . Composition of claim 1 wherein the dose amount of the THC is 1.0 mg up to 2.5 mg and the dose amount of the melatonin is 14 μg up to 1.5 mg.
4 . Composition of claim 3 which is a 1 mL oral suspension.
5 . Composition of claim 1 wherein the THC is selected from the group consisting of dronabinol, Δ9-THC, Δ8-THC, and THC Acid (THCA).
6 . Composition of claim 1 wherein the curcumin is selected from the group consisting of turmeric, and mixtures thereof.
7 . Composition of claim 1 in a liquid carrier further comprising a non-ionic emulsifier in an amount sufficient to maintain stability and solubility of the composition.
8 . Composition of claim 7 , wherein the non-ionic emulsifier is selected from the group consisting of soy lecithin, sunflower lecithin, polysorbate 80, and D-α-tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS).
9 . Composition of claim 1 further comprising an anti-fungal agent.
10 . Composition of claim 9 , wherein the anti-fungal agent is a natural anti-fungal agent.
11 . Composition for treating a human suffering from Alzheimer's disease; the composition comprising dose amounts per 70 kg-person weight as follows:
(i) tetrahydrocannabinol (THC) from about 2.0 mg up to 2.5 mg,
(ii) melatonin from about 0.7 mg to about 10.0 mg, and
(iii) curcumin up to 0.5 mg.
12 . Composition of claim 11 further comprising polysorbate 80, D-α-tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS), ethanol, and water.
13 . Composition of claim 11 which is a 1 mL oral suspension.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 15, 2024
From: IGC PHARMA, INC.
To: IGC PHARMA IP, LLC
Reel/Frame 066792/0283 →
CHANGE OF NAME
Recorded Mar 15, 2024
From: INDIA GLOBALIZATION CAPITAL, INC.
To: IGC PHARMA, INC.
Reel/Frame 066801/0258 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 14, 2023
From: MUKUNDA, RAMACHANDRA; RAO, JAGADEESH S.; MUKUNDA, AMAR R.
To: INDIA GLOBALIZATION CAPITAL, INC.
Reel/Frame 063331/0446 →
Continuity (3)
Division
17042333
Provisional Application
62650942
· Mar 30, 2018
References Cited (393)
US 5804592A
· Volicer
· 1998
[cited by applicant]
US 6503532B1
· Murty et al.
· 2003
[cited by applicant]
US 6630507B1
· Hampson et al.
· 2003
[cited by applicant]
US 6730330B2
· Whittle et al.
· 2004
[cited by applicant]
US 7678363B2
· Barlow et al.
· 2010
[cited by applicant]
US 7906643B2
· DiMauro
· 2011
[cited by applicant]
US 8673368B2
· Guy et al.
· 2014
[cited by applicant]
US 9168278B2
· Guy et al.
· 2015
[cited by applicant]
US 9205063B2
· Guy et al.
· 2015
[cited by applicant]
US 9738605B2
· Zhang
· 2017
[cited by applicant]
US 20050031651A1
· Gervais et al.
· 2005
[cited by applicant]
US 20050042172A1
· Whittle
· 2005
[cited by applicant]
US 20080033027A1
· Bascomb et al.
· 2008
[cited by applicant]
US 20080112895A1
· Kottayil et al.
· 2008
[cited by applicant]
US 20100292345A1
· Pertwee
· 2010
[cited by applicant]
US 20110257256A1
· Fuchs et al.
· 2011
[cited by applicant]
US 20130281523A1
· Letendre et al.
· 2013
[cited by applicant]
US 20180071210A1
· Wilkhu et al.
· 2018
[cited by applicant]
US 20190201372A1
· Mckay
· 2019
[cited by applicant]
US 20200037638A1
· Faraci et al.
· 2020
[cited by applicant]
US 20200046722A1
· Mukunda
· 2020
[cited by applicant]
US 20200246404A1
· Yucel et al.
· 2020
[cited by applicant]
US 20200383935A1
· Mukunda et al.
· 2020
[cited by applicant]
US 20210023053A1
· Mukunda et al.
· 2021
[cited by applicant]
US 20210059976A1
· Wilkhu et al.
· 2021
[cited by applicant]
US 20210353705A1
· Mukunda et al.
· 2021
[cited by applicant]
US 20220241244A1
· Mukunda et al.
· 2022
[cited by applicant]
US 20220265599A1
· Cao
· 2022
[cited by applicant]
US 20220280613A1
· Cao
· 2022
[cited by applicant]
US 20220370531A1
· Obias et al.
· 2022
[cited by applicant]
US 20240009207A1
· Mukunda et al.
· 2024
[cited by applicant]
EP 2640379
· 2013
[cited by applicant]
GB 2434312A
· 2007
[cited by applicant]
WO 9850027A1
· 1998
[cited by applicant]
WO 02064109A2
· 2002
[cited by applicant]
WO 2005077394A1
· 2005
[cited by applicant]
WO 2007083098A1
· 2007
[cited by applicant]
WO 2010012506A1
· 2010
[cited by applicant]
WO 2010045577A2
· 2010
[cited by applicant]
WO 2012068516A2
· 2012
[cited by applicant]
WO 2016044370A1
· 2016
[cited by applicant]
WO 2016071819A1
· 2016
[cited by applicant]
WO 2016118391A1
· 2016
[cited by applicant]
WO 2016160542A1
· 2016
[cited by applicant]
WO 2017027651A1
· 2017
[cited by applicant]
WO 2017218629A1
· 2017
[cited by applicant]
WO 2018002665A1
· 2018
[cited by applicant]
WO 2018152334A1
· 2018
[cited by applicant]
WO 2018160510A1
· 2018
[cited by applicant]
WO 2019036243A1
· 2019
[cited by applicant]
WO 2019135077A1
· 2019
[cited by applicant]
WO 2019190608A1
· 2019
[cited by applicant]
WO 2020072997A1
· 2020
[cited by applicant]
WO 2020237247A1
· 2020
[cited by applicant]
WO 2021011421A1
· 2021
[cited by applicant]
WO 2022016160A1
· 2022
[cited by applicant]
WO 2023044433
· 2023
[cited by applicant]
Drugs.com. “Drugs used to treat Alzheimer's Disease.” Retrieved from the Internet on Nov. 16, 2023, https://www.drugs.com/condition/alzheimer-s-disease.html (Year: 2023).
[cited by examiner]
Drugs.com. Polysorbated. Publised Jul. 17, 2017. Retrieved from the Wayback Machine on Feb. 22, 2024, https://web.archive.org/web/20170717070355/https://www.drugs.com/inactive/polysorbate-176.html (Year: 2017).
[cited by examiner]
Fishbein et al. Long-term behavioral and biochemical effects of an ultra-low dose of THC: neuroprotection and ERK signaling. Exp. Brain Research (2012) 221:437-448. (Year: 2012).
[cited by examiner]
Steinmann J, Buer J, Pietschmann T, Steinmann E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br J Pharmacol. Mar. 2013;168(5):1059-73. doi: 10.1111/bph. 12009. (Year: 2013).
[cited by examiner]
Guo et al. European Journal of Pharmaceutical Sciences. The applications of Vitamin E TPGS in drug delivery. Published 2013. (Year: 2013).
[cited by examiner]
Buckley et al. Bedside Method to Estimate Actual Body Weight in the Emergency Department. The Journal of Emergency Medicine. Published 2011. (Year: 2011).
[cited by examiner]
Cao, Chuanhai et al. ‘The Potential Therapeutic Effects of THC on Alzheimer's Disease’. Jan. 1, 2014 : 973 984. (Year: 2014).
[cited by examiner]
MayoClinic. Cruetzfeldt-Jakob disease. Retrieved from the Internet on Mar. 31, 2025, https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055. (Year: 2025).
[cited by examiner]
Sagredo, O., Pazos, M.R., Satta, V., Ramos, J.A., Pertwee, R.G. and Fernández-Ruiz, J. (2011), Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease. J. Neurosci. Res…
[cited by examiner]
Abate et al. “Potential and limits of cannabinoids in Alzheimer's disease therapy” Biology; Jun. 2021; 10(6): 542, doi: 10.3390/biology10060542, 21 pages.
[cited by applicant]
Abbvie Inc. “Marinol (dronabinol) capsules prescribing information” Reference ID: 4145204; Aug. 2017; www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf, 20 pages.
[cited by applicant]
Aggarwal et al. “Curcumin differs from tetrahydrocurcumin for molecular targets, signaling pathways and cellular responses” Molecules; Dec. 2014; 20(1): 185-205.
[cited by applicant]
Ahmed et al. “Safety, pharmacodynamics, and pharmacokinetics of multiple oral doses of delta-9-tetrahydrocanna-binol in older persons with dementia” Psychopharmacology (Berl); Jul. 2015 ePub Mar. 2015; 232(14): 2587-259…
[cited by applicant]
Ahmed Clinical Pharmacology of Oral Tetrahydrocannabinol in Older People with Dementia; Radboud University Nijmegen, Nijmegen, NL; Sep. 2016; 316 pages.
[cited by applicant]
Akirav “The role of cannabinoids in modulating emotional and nonemotional memory processes in the hippocampus” Front Behav Neurosci; Jun. 2011; 5: 34, doi: 10.3389/fnbeh.2011.00034, 11 pages.
[cited by applicant]
Alsherbiny & Li “Medicinal cannabis—Potential drug interactions” Medicines; Dec. 2018; 6(1): 3, doi: 10.3390/medicines6010003, 12 pages.
[cited by applicant]
Amanullah et al. “Synthetic cannabinoids in dementia with agitation: Case studies and literature review” Clin Neuropsychiatry; Jun.-Aug. 2013 ePub Jan. 2013; 10(3-4): 142-147.
[cited by applicant]
Amin & Ali “Pharmacology of medical cannabis” Adv Exp Med Biol; Jul. 2019; 1162: 151-165.
[cited by applicant]
Andersen et al. “Pharmacokinetics of oral and intravenous melatonin in healthy volunteers” BMC Pharmacol Toxicol; Feb. 2016; 17: 8, doi: 10.1186/s40360-016-0052-2, five pages.
[cited by applicant]
Arendash & Cao “Caffeine and coffee as therapeutics against Alzheimer's disease” J Alzheimer Dis; Apr. 2010; 20(S1): S117-S126.
[cited by applicant]
Aso & Ferrer “Cannabinoids for treatment of Alzheimer's disease: Moving toward the clinic” Front Pharmacol; Mar. 2014; 5: 37, doi: 10.3389/fphar.2014.00037, 11 pages.
[cited by applicant]
Aso et al. “Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice” J Alzheimers Dis; Jan. 2015; 43(3): 977-991.
[cited by applicant]
Aso et al. “Cannabinoid receptor 2 participates in amyloid-β processing in a mouse model of Alzheimer's disease but plays a minor role in the therapeutic properties of a cannabis-based medicine” J Alzheimers Dis; Feb. 2…
[cited by applicant]
Aso et al. “Delineating the efficacy of a cannabis-based medicine at advanced stages of dementia in a murine model” J Alzheimers Dis; Oct. 2016; 54(3): 903-912.
[cited by applicant]
Bahij et al. “Cannabinoids for the neuropsychiatric symptoms of dementia: A systematic review and meta-analysis” Can J Psychiatry; Jun. 2020 ePub Dec. 2019; 65(6): 365-376.
[cited by applicant]
Bahij et al. “Cannabinoids in the management of behavioral, psychological, and motor symptoms of neurocognitive disorders: A mixed studies systematic review” J Cannabis Res; Mar. 2022; 4(1): 11, doi: 10.1186/s42238-022-…
[cited by applicant]
Baratta et al. “Cannabis for medical use: Analysis of recent clinical trials in view of current legislation” Front Pharmacol; May 20222; 13: 888903, doi: 10.3389/fphar.2022.888903, 17 pages.
[cited by applicant]
Benito et al. “Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains” J Neurosci; Dec. 2003; 23(35): 11136-11141.
[cited by applicant]
Bhatti et al. “Lifestyle modifications and nutritional interventions in aging-associated cognitive decline and Alzheimer's disease” Front Aging Neurosci; Jan. 2020; 11: 369, doi: 10.3389/fnagi.2019.00369, 15 pages.
[cited by applicant]
Bilbao & Spanagel “Medical cannabinoids: A pharmacology-based systematic review and meta-analysis for all relevant medical indications” BMC Med; Aug. 2022; 20(1): 259, doi: 10.1186/s12916-022-02459-1, 29 pages.
[cited by applicant]
Bilkei-Gorzo et al. “A chronic low dose of Δ9-tetrahydrocannabinol (THC) restores cognitive function in old mice” Nature Med; Jun. 2017; 23(6): 782-787.
[cited by applicant]
Bisogno & Di Marzo “Cannabinoid receptors and endocannabinoids: Role in neuroinflammatory and neurodegenerative disorders” CNS Neurol Disord Drug Targets; Nov. 2010; 9(5): 564-573.
[cited by applicant]
Black et al. “Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: A systematic review and meta-analysis” Lancet Psychiatry; Dec. 2019 Epub ; 6(12): 995-1010.
[cited by applicant]
Boggs et al. “Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol” Neuropsychopharmacol; Jan. 2018 ePub Oct. 2017; 43(1): 142-154.
[cited by applicant]
Bosnjak Kuharic et al. “Cannabinoids for the treatment of dementia” Cochrane Database Syst Rev; Sep. 2021; 9(9): CD012820, doi: 10.1002/14651858.CD012820_pub2, 77 pages.
[cited by applicant]
Botsford et al. “Cannabis and cannabinoids in mood and anxiety disorders: Impact on illness onset and course, and assessment of therapeutic potential” Am J Addict; Jan. 2020; 29(1): 9-26.
[cited by applicant]
Breijyeh et al. “Cannabis: A toxin-producing plant with potential therapeutic uses” Toxin; Feb. 2021; 13: 117, doi: 10.3390/toxins13020117, 29 pages.
[cited by applicant]
Briggs et al. “Drug treatments in Alzheimer's disease” Clin Med; Jun. 2016; 16(3): 247-253.
[cited by applicant]
Broers et al. “Prescription of a THC/CBD-based medication to patients with dementia: A pilot study in Geneva” Med Cannabis Cannabinoids; Apr. 2019; 2(1): 56-59.
[cited by applicant]
Brown & Winterstein “Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use” J Clin Med; Jul. 2019; 8(7): 989; doi:10.3390/jcm8070989, 14 pages.
[cited by applicant]
Bui & Nguyen “Natural product for the treatment of Alzheimer's disease” J Basic Clin Physiol Pharmacol; Jul. 2017; 28(5): 413-423.
[cited by applicant]
Calabrese et al. “Biphasic effects of THC in memory and cognition” Eur J Clin Invest; May 2018; 48(5): e12920, nine pages.
[cited by applicant]
Campbell & Gowran “Alzheimer's disease; taking the edge off with cannabinoids?” Br J Pharmacol; Nov. 2007; 152(5): 655-662.
[cited by applicant]
Cao et al. “Caffeine suppresses β-amyloid levels in plasma and brain of Alzheimer's transgenic mice” J Alzheimer Dis; Sep. 2009; 17(3): 681-697.
[cited by applicant]
Cao et al. “The potential therapeutic effects of THC on Alzheimer's disease” J Alzheimer Dis; Sep. 2014; 42(3): 973-984.
[cited by applicant]
Cardinali et al. “Melatonin therapy in patients with Alzheimer's disease” Antioxidant; Jun. 2014; 3(2): 245-277.
[cited by applicant]
Cardinali “Melatonin: Clinical perspectives in neurodegeneration” Front Endocrinol; Jul. 2019; 10: 480, doi: 10.3389/fendo.2019.00480, 22 pages.
[cited by applicant]
Casarejos et al. “Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy” J Alzheimers Dis; May 2013; 35(3): 525-539.
[cited by applicant]
Cenini & Voos “Mitochondria as potential targets in Alzheimer disease therapy: An update” Front Pharmacol; Aug. 2019; 10: 902, doi: 10.3389/fphar.2019.00902, 20 pages.
[cited by applicant]
Chainoglou & Hadjipavlou-Litina “Curcumin in health and diseases: Alzheimer's disease and curcumin analogues, derivatives, and hybrids” Int J Mol Sci; Mar. 2020; 21(6): 1975, doi:10.3390/ijms21061975, 55 pages.
[cited by applicant]
Chen et al.“Pharmacological properties of rutin and its potential uses for Alzheimer's disease” Exp Stroke Translat Med; Feb. 2021; 13(2): 1-12.
[cited by applicant]
Chitimus et al. “Melatonin's impact on antioxidative and anti-inflammatory reprogramming in homeostasis and disease” Biomolecules; Aug. 2020; 10(9): 1211, doi: 10.3390/biom10091211, 28 pages.
[cited by applicant]
Cohen-Mansfield et al. “Melatonin for treatment of sundowning in elderly persons with dementia—A preliminary study” Arch Gerontol Geriatr, Aug. 2000; 31(1): 65-76.
[cited by applicant]
Cooray et al. “Current aspects of the endocannabinoid system and targeted THC and CBD phytocannabinoids as potential therapeutics for Parkinson's and Alzheimer's diseases” Mol Neurobiol; Nov. 2020 ePub Aug. 2020; 57(11)…
[cited by applicant]
Crippa et al. “Translational investigation of the therapeutic potential of cannabidiol (CBD): Toward a new age” Front Immunol; Sep. 2018; 9: 2009, doi: 10.3389/fimmu.2018.02009, 16 pages.
[cited by applicant]
Croxford “Therapeutic potential of cannabinoids in CNS disease” CNS Drugs; Mar. 2003; 17(3): 179-202.
[cited by applicant]
Cummings “New approaches to symptomatic treatments for Alzheimer's disease” Mol Neurodegener; Jan. 2021; 16(1): 2, doi: 10.1186/s13024-021-00424-9, 13 pages.
[cited by applicant]
Cummings et al. “Alzheimer's disease drug development pipeline: 2021” Alzheimers Dement; May 2021; 7(1): e12179, doi: 10.1002/trc2.12179, 24 pages.
[cited by applicant]
Ahmed et al. “Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy subjects: A randomized controlled trial” Eur Neuropsychopharmacol; Sep. 2014 ePub Jun. 2014; 24(9): 1475-1482.
[cited by applicant]
Van den Elsen et al. “Tetrahydrocannabinol in behavioral disturbances in dementia: A crossover randomized controlled trial” Am J Geriatr Psychiatry; Dec. 2015 ePub Jul. 2015; 23(12): 1214-1224.
[cited by applicant]
Van den Elsen Tetrahydrocannabinol in the Treatment of Neuropsychiatric Symptoms in Dementia; Ph.D. Thesis presented to Radboud University Nijmegen, Nijmegen, NL; Mar. 2016; 217 pages.
[cited by applicant]
Pauli et al. “Cannabidiol drugs clinical trial outcomes and adverse effects” Front Pharmacol; Feb. 2020; 11: 63, doi: 10.3389/fphar.2020.00063, six pages.
[cited by applicant]
Paunescu et al. “A systematic review of clinical studies on the effect of psychoactive cannabinoids in psychiatric conditions in Alzheimer dementia” Am J Ther; May 2020; 27(3): e249-e269.
[cited by applicant]
Dos Santos et al. “Neuropharmacological effects of the main phytocannabinoids: A narrative review” Adv Exp Med Biol; Dec. 2020; 1264: 29-45.
[cited by applicant]
Canadian Intellectual Property Office “Office Action” for corresponding Canadian Application No. 3,095,729.
[cited by applicant]
Babayeva et al. “Marijuana compounds: A nonconventional approach to Parkinson's disease therapy” Parkinsons Dis; Dec. 2016; 2016: 1279042, doi: 10.1155/2016/1279042; 19 pages.
[cited by applicant]
Stoner “Effects of marijuana on mental health: Anxiety disorders” Alcohol & Drug Abuse Institute, University of Washington, Seattle, WA; Jun. 2017; http://adai.uw.edu/pubs/pdf/2017mjanxiety.pdf; six pages.
[cited by applicant]
IGC Pharma “Study of IGC-AD1 in subjects with dementia due to Alzheimer's disease” ClinicalTrials.gov ID NCT04749563, National Library of Medicine, Bethesda, MD; downloaded from clinicaltrials.gov/study/NCT04749563 on J…
[cited by applicant]
IGC Pharma “IGC-AD1 trial on agitation in dementia due to Alzheimer's (IGC-AD1-P2)” ClinicalTrials.gov ID NCT05543681, National Library of Medicine, Bethesda, MD; downloaded from clinicaltrials.gov/study/NCT04749563 on …
[cited by applicant]
India Globalization Capital “IGC announces IRB approval of its IGC-AD1 for a phase-2 study” IGC press release, Bethesda, MD; Sep. 19, 2019; one page.
[cited by applicant]
India Globalization Capital “FDA approves initiation of IGC's cannabinoid trial on Alzheimer's patients” IGC press release, Potomac, MD; Aug. 11, 2020; one page.
[cited by applicant]
India Globalization Capital “IGC commences phase 1 of cannabinoid clinical trial for Alzheimer's patients” IGC press release, Potomac, MD; Nov. 23, 2020; two pages.
[cited by applicant]
India Globalization Capital “Update on IGC's phase 1 clinical trial on Alzheimer's patients” IGC press release, Potomac, MD; Feb. 22, 2021; two pages.
[cited by applicant]
India Globalization Capital “India Globalization Capital (IGC) completes cohort 1 of its phase 1 THC-based clinical trial on Alzheimer's patients” IGC press release, Potomac, MD; May 14, 2021; two pages.
[cited by applicant]
India Globalization Capital “IGC completes cohort 2 of its phase 1 THC-based clinical trial on Alzheimer's patients” IGC press release, Potomac, MD; Jun. 7, 2021; two pages.
[cited by applicant]
India Globalization Capital “IGC completes the final cohort of its phase 1 clinical trial on Alzheimer's patients” IGC press release, Potomac, MD; Jun. 23, 2021; one page.
[cited by applicant]
India Globalization Capital “IGC completes its phase 1 clinical trial on Alzheimer's patients, Reports safety and tolerability” IGC press release, Potomac, MD; Sep. 7, 2021; one page.
[cited by applicant]
India Globalization Capital “Phase 1 clinical trial data indicate IGC's THC-based investigational new drug may reduce symptoms of dementia in Alzheimer's patients” IGC press release, Potomac, MD; Dec. 2, 2021; two pages.
[cited by applicant]
India Globalization Capital “IGC commences phase 2 clinical trials evaluating drug candidate IGC-AD1 for the treatment of agitation in dementia from Alzheimer's disease” IGC press release, Potomac, MD; Dec. 1, 2022; two…
[cited by applicant]
India Globalization Capital “IGC receives no objection letter from Health Canada” IGC press release, Potomac, MD; Jan. 4, 2023; three pages.
[cited by applicant]
IGC Pharma “IGC Pharma, Inc. presenting 6 posters on the positive impact of IGC-AD1 on neuropsychiatric symptoms in dementia at the 2023 Alzheimer's Association International Conference” IGC Pharma press release, Potoma…
[cited by applicant]
IGC Pharma “IGC Pharma expands phase 2 trial of IGC-AD1 to include the University of Puerto Rico” IGC Pharma press release, Potomac, MD; Aug. 2, 2023; two pages.
[cited by applicant]
Ashmore “IGC Pharma advances In Alzheimer's research from pre-clinical studies to phase two trial with its novel therapy candidate IGC-AD1” Benzinga; Mar. 2024; https://www.benzinga.com/partner/biotech/24/03/37819235/ig…
[cited by applicant]
Cohen et al. “Study rationale and baseline data for pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's dementia (THC-AD)” International Psychogeriatrics; Oct. 2021; doi: 10.1017/S1041610221001150…
[cited by applicant]
drugs.com “Medications for Alzheimer's disease” Drugsite Limited, Dallas, TX(?); downloaded Mar. 15, 2025; https://www.drugs.com/condition/alzheimer-s-disease.html, three pages.
[cited by applicant]
drugs.com “Medications for agitation associated with dementia due to Alzheimer's disease” Drugsite Limited, Dallas, TX(?); downloaded Mar. 15, 2025; https://www.drugs.com/condition/agitation-associated-with-dementia-due…
[cited by applicant]
Higginbotham “Revolutionary Alzheimer's drug by IGC shows early success” Benzinga; Mar. 2024; hhttps://www.benzinga.com/general/health-care/24/03/37854695/exclusive-revolutionary-alzheimers-drug-by-igc-shows-early-succe…
[cited by applicant]
Di Marzo “New approaches and challenges to targeting the endocannabinoid system” Nature Reviews Drug Discovery; Sep. 2018 ePub Aug. 2018; 17(9): 623-639.
[cited by applicant]
De Mauleon et al. “Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria” Alzheimer's & Dementia; Oct. 2021 ePub Jan. 2021; 17(10): 16…
[cited by applicant]
Mehta “Protein folding: A new twist on brain disease” BrainFacts/SfN, Washington, DC(?); May 2010; www.brainfacts.org/archives/2010/protein-folding-a-new-twist-on-brain-disease, three pages.
[cited by applicant]
Rosenberg et al. “Trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (AD) (THC-AD)” American Journal of Geriatric Psychiatry; Apr. 2020; 28(4) Suppl: S121-S122, Poster NR-2.
[cited by applicant]
Rosenberg et al. “Pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's disease (THC-AD)” Alzheimer's & Dementia; Jun. 2023; 19(Suppl 4): e064983, doi: 10.1002/alz.064983, three pages.
[cited by applicant]
Ruthirakuhan et al. “Natural and synthetic cannabinoids for agitation and aggression in Alzheimer's disease: A meta-analysis” Journal of Clinical Psychiatry; Jan. 2019; 80(2): 18r12617, abstract only.
[cited by applicant]
Karasek et al. “Future of melatonin as a therapeutic agent” Neuro Endocrinol Lett; Apr. 2002; 23(suppl 1): 181-121.
[cited by applicant]
Karl et al. “The therapeutic potential of the endocannabinoid system for Alzheimer's disease” Expert Opin Ther Targets; Apr. 2012; 16(4):407-420.
[cited by applicant]
Kim et al. “A review on studies of marijuana for Alzheimer's disease—Focusing on CBD, THC” J Pharmacopuncture; Dec. 2019; 22(4): 225-230.
[cited by applicant]
Kocis & Vrana “Delta-9-tetrahydrocannabinol and cannabidiol drug-drug interactions” Med Cannabis Cannabinoids; Aug. 2020 ePub Jul. 2020; 3(1): 61-73.
[cited by applicant]
Kogan & Mechoulam “Cannabinoids in health and disease” Dialogues Clin Neurosci; Dec. 2007; 9(4): 413-430.
[cited by applicant]
Kopustinskiene et al. “Molecular mechanisms of melatonin-mediated cell protection and signaling in health and disease” Pharmaceutics; Jan. 2021; 13(2): 129, doi: 10.3390/pharmaceutics13020129, 19 pages.
[cited by applicant]
Kopustinskiene et al. “Cannabis sativa L. bioactive compounds and their protective role in oxidative stress and inflammation” Antioxidants (Basel); Apr. 2022; 11(4): 660, doi: 10.3390/antiox11040660, 12 pages.
[cited by applicant]
Lacroix et al. “What do we know about medical cannabis in neurological disorders and what are the next steps?” Front Pharmacol; Apr. 2022; 13: 883987, doi: 10.3389/fphar.2022.883987, ten pages.
[cited by applicant]
Lanctôt et al. “Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms” Alzheimers Dement; Aug. 2017; 3(3): 440-449.
[cited by applicant]
Laux et al. “Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results” Epilepsy Res; Aug. 2019 ePub Mar. 20…
[cited by applicant]
Legare et al. “Therapeutic potential of cannabis, cannabidiol, and cannabinoid-based pharmaceuticals” Pharmacology; Mar. 2022 ePub Jan. 2022; 107(3-4): 131-149.
[cited by applicant]
Lim et al. “A systematic review of the effectiveness of medical cannabis for psychiatric, movement and neurodegenerative disorders” Clin Psychopharmcol Neurosci; Nov. 2017; 15(4): 301-312.
[cited by applicant]
Lin et al. “Melatonin in Alzheimer's disease” Int J Mol Sci; Jul. 2013; 14(7): 14575-14593.
[cited by applicant]
Lin et al. “Trough melatonin levels differ between early and late phases of Alzheimer disease” Clin Psychopharmacol Neurosci; Feb. 2021; 19(1): 135-144.
[cited by applicant]
Liu et al. “Cannabinoids for the treatment of agitation and aggression in Alzheimer's disease” CNS Drugs; Aug. 2015; 29(8): 615-623.
[cited by applicant]
Liu et al. “Pharmacological treatment trials of agitation in Alzheimer's disease: A systematic review of ClinicalTrials.gov registered trials” Alzheimers Dement; Mar. 2021; 7(1): e12157, doi: 10.1002/trc2.12157, 18 page…
[cited by applicant]
Lowe et al. “Cannabis and mental illness: A review” Eur Arch Psychiatry Clin Neurosci; Feb. 2019; 269(1): 107-120.
[cited by applicant]
Lucas et al. “The pharmacokinetics and the pharmacodynamics of cannabinoids” Br J Clin Pharmcol; Nov. 2018 ePub Aug. 2018; 84(11): 2477-2482.
[cited by applicant]
Maiti & Dunbar “Use of curcumin, a natural polyphenol for targeting molecular pathways in treating age-related neurodegenerative diseases” Int J Mol Sci; May 2018; 19(6): 1637, doi: 10.3390/ijms19061637, 42 pages.
[cited by applicant]
Mannucci et al. “Neurological aspects of medical use of cannabidiol” CNS Neurol Disord Drug Targets; Aug. 2017; 16(5): 541-553.
[cited by applicant]
Marchalant et al. “Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis” Neurobiol Dis; May 2009; 34(2): 300-307.
[cited by applicant]
Markovic et al. “Cannabinoids for the treatment of dementia” Cochrane Database Syst Rev; Oct. 2017; 2017(10): CD012820, doi: 10.1002/14651858.CD012820, 14 pages.
[cited by applicant]
Maroon & Bost “Review of the neurological benefits of phytocannabinoid” Surg Neurol Int; Apr. 2018; 9: 91, doi: 10.4103/sni.sni_45_18, 13 pages.
[cited by applicant]
Matsubara et al. “Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease” J Neurochem; Jun. 2003; 85(5): 1101-1108.
[cited by applicant]
Maurizi et al. “The mystery of Alzheimer's disease and its prevention by melatonin” Med Hypotheses; Oct. 1995, 45(4): 339-340.
[cited by applicant]
McCleery et al. “Pharmacotherapies for sleep disturbances in dementia” Cochrane Database Syst Rev; Nov. 2016; 11(11): CD009178, doi: 10.1002/14651858.CD009178.pub3, 55 pages.
[cited by applicant]
McCormick et al. The Health Effects of Cannabis and Cannabinoids; Washington DC: The National Academies Press; Jan. 2017; doi: 10.17226/24625, xviii + 468 pages.
[cited by applicant]
Mehta “Protein folding: A new twist on brain disease” BrainFacts/SfN; May 2010; www.brainfacts.org/archives/2010/protein-folding-a-new-twist-on-brain-disease.
[cited by applicant]
Milano et al. “Cannabinoids involvement in neurodegenerative diseases” Curr Neurobiol; Oct. 2017; 8(3): 135-144.
[cited by applicant]
Milano & Capasso “Neuroprotection by cannabinoids in neurodegenerative diseases” Alzheimers Dement Cogn Neurol; Jan. 2018; 2(1): 1-7, doi: 10.15761/ADCN.1000120, seven pages.
[cited by applicant]
Millar et al. “A systematic review on the pharmacokinetics of cannabidiol in humans” Front Pharmcol; Nov. 2018; 9: 1365, doi: org/10.3389/fphar.2018.01365, 13 pages.
[cited by applicant]
Millar et al. “A systematic review of cannabidiol dosing in clinical populations” Br J Clin Pharmacol; Sep. 2019 ePub Jul. 2019; 85(9): 1888-1900.
[cited by applicant]
Mohorko et al. “Curcumin labeling of neuronal fibrillar tau inclusions in human brain samples” J Neuropathol Exp Neurol; Apr. 2010; 69(4): 405-414.
[cited by applicant]
Monmouth Medical Center “Synthetic marijuana reduces agitation in patients with Alzheimer's” Science Daily; Nov. 2003, www.eurekalert.org/news-releases/480207, two pages.
[cited by applicant]
Monteiro et al. “Cannabinoid pharmacology and its therapeutic uses in Alzheimer's disease” Neural Regener Res; May 2021; 16(5): 990-991.
[cited by applicant]
Mouli et al. “Balancing the neuroprotective versus neurotoxic effects of cannabis” in Medicinal Herbs and Fungi (Agrawal & Dhanasekaran, eds.); Jan. 2021; 203-226, doi: 10.1007/978-981-33-4141-8_8, 24 pages.
[cited by applicant]
Mutsuga et al. “Binding of curcumin to senile plaques and cerebral amyloid angiopathy in the aged brain of various animals and to neurofibrillary tangles in Alzheimer's brain” J Vet Med Sci; May 2018; 74(1): 51-57.
[cited by applicant]
Nidadavolu et al. “Efficacy of Δ9-tetrahydrocannabinol (THC) alone or in combination with a 1:1 ratio of cannabidiol (CBD) in reversing the spatial learning deficits in old mice” Front Aging Neurosci; Aug. 2021; 13: 718…
[cited by applicant]
Nitzan et al. “An ultra-low dose of Δ9-tetrahydrocannabinol alleviates Alzheimer's disease-related cognitive impairments and modulates TrkB receptor expression in a 5XFAD mouse model” Int J Mol Sci; Aug. 2022; 23(16): 9…
[cited by applicant]
Noel “Evidence for the use of ‘medical marijuana’ in psychiatric and neurologic disorders” Ment Health Clin; Mar. 2018 ePub Jan. 2017; 7(1): 29-38.
[cited by applicant]
Oberbarnscheidt & Miller “The impact of cannabidiol on psychiatric and medical conditions” J Clin Med Res; Jun. 2020; 12(7): 393-403.
[cited by applicant]
Olcese et al. “Protection against cognitive deficits and markers of neurodegeneration by long term oral administration of melatonin in a transgenic model of Alzheimer disease” J Pineal Res; Aug. 2009 ePub Jun. 2009; 47(…
[cited by applicant]
O'Neal-Moffitt et al. “Prophylactic melatonin significantly reduces Alzheimer's neuropathology and associated cognitive deficits independent of antioxidant pathways in AβPPswe/PS1 mice” Mol Neurodegener; Jul. 2015; 10: …
[cited by applicant]
Ortiz et al. “Medicinal cannabis and central nervous system disorders” Front Pharmacol; Apr. 2022; 13: 881810, doi: 10.3389/fphar.2022.881810, 24 pages.
[cited by applicant]
Outen et al. “Cannabinoids for agitation in Alzheimer's disease” Am J Geriatr Psychiary; Dec. 2021 ePub Jan. 2021; 29(12): 1253-1263, doi: 10.1016/j.jagp.2021.01.015, 11 pages.
[cited by applicant]
Paes-Colli et al. “Phytocannabinoids and cannabis-based products as alternative pharmacotherapy in neurodegenerative diseases: From hypothesis to clinical practice” Front Cell Neurosci; May 2022; 16: 917164; doi: 10.338…
[cited by applicant]
Passmore “The cannabinoid receptor agonist nabilone for the treatment of dementia-related agitation” Int J Geriatr Psychiatry; Jan. 2008; 23(1): 116-117.
[cited by applicant]
Peprah & McCormack “Medical cannabis for the treatment of dementia: A review of clinical effectiveness and guidelines” Ottawa: The Canadian Agency for Drugs and Technologies in Health; Jul. 2019; 24 pages.
[cited by applicant]
Perry & Howes “Medicinal plants and dementia rherapy: Herbal hopes for brain aging?” CNS Neurosci Ther; Oct. 2010; 17(6): 683-698.
[cited by applicant]
Pertwee “The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: ΔA9-tetrahydrocanna-binol, cannabidiol and Δ9-tetrahydrocannabivarin” Br J Pharmacol; Jan. 2008 ePub Sep. 2007;153(2): 199-215.
[cited by applicant]
Pocuca et al. “The effects of cannabis use on cognitive function in healthy aging: A systematic scoping review” Arch Clin Neuropsychol; Aug. 2021 ePub Nov. 2020; 36(5): 673-685.
[cited by applicant]
Ramírez et al. “Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation” J Neurosci; Feb. 2005; 25(8): 1904-1913.
[cited by applicant]
Reddy et al. “Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: Implications to mitochondria-targeted antioxidant therapeutics” Biochim Biophys Acta; May 2012; 1822(5): 63…
[cited by applicant]
Reddy et al. “Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer's disease” J Invest Med; Aug. 2016; 64(8): 1220-1234.
[cited by applicant]
Reddy et al. “Protective effects of Indian spice curcumin against amyloid beta in Alzheimer's disease” J Alzheimers Dis; Feb. 2018; 61(3): 843-866.
[cited by applicant]
Reddy et al. “Targeting the endocannabinoid system: A predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies” EPMA J; Apr. 2020; 11(2): 217-250.
[cited by applicant]
Rosenberg et al. “Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection” Epilepsy Behav; May 2017; 70(part B): 319-327.
[cited by applicant]
Roy et al. “Regulation of melatonin and neurotransmission in Alzheimer's disease” Int J Mol Sci; Jun. 2021; 22(13): 6841, doi: 10.3390/ijms22136841, 17 pages.
[cited by applicant]
Rudnitskaya et al. “Melatonin attenuates memory impairment, amyloid-β accumulation, and neurodegeneration in a rat model of sporadic Alzheimer's disease” J Alzheimers Dis; Jul. 2015; 47(1): 103-116.
[cited by applicant]
Ruthirakuhana et al. “Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial…
[cited by applicant]
Ruver-Martins et al. “Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer's disease symptoms: A case report” J Med Case Rep; Jul. 2022; 16(1): 277, doi: 10.1186/s13256-022-03457-w, seven pag…
[cited by applicant]
Salthouse “When does age-related cognitive decline begin?” Neurobiol Aging; Apr. 2009; 30(4): 507-514.
[cited by applicant]
Sarne et al. “The dual neuroprotective-neurotoxic profile of cannabinoid drugs” Br J Pharmacol; Aug. 2011; 163(7): 1391-1401.
[cited by applicant]
Sarne “THC for age-related cognitive decline?” Aging; Nov. 2018; 10(12): 3628-3629.
[cited by applicant]
Sarne “Beneficial and deleterious effects of cannabinoids in the brain: The case of ultra-dose THC” Am J Drug Alcohol Use; Mar. 2019; 45(6): 551-562.
[cited by applicant]
Sarris et al. “Medicinal cannabis for psychiatric disorders: A clinically-focused systematic review” BMC Psychiatry; Jan. 2020; 20(1): 24, doi: 10.1186/s12888-019-2409-8, 14 pages.
[cited by applicant]
Schott et al. “New criteria for Alzheimer's disease: Which, when and why?” Brain; May 2015 ePub Apr. 2015; 138 (pt 5): 1134-1137.
[cited by applicant]
Schreiner & Popescu “Impact of caffeine on Alzheimer's disease pathogenesis—Protective or risk factor?” Life (Basel); Feb. 2022; 12(3): 330, doi: 10.3390/life12030330, 18 pages.
[cited by applicant]
Scott et al. “Association of cannabis with cognitive functioning in adolescents and young adults: A systematic review and meta-analysis” JAMA Psychiatry; Jun. 2018; 75(6): 585-595.
[cited by applicant]
Scott et al. “A systematic review of the neurocognitive effects of cannabis use in older adults” Cur Addict Rep; Dec. 2019; 6(4): 443-455.
[cited by applicant]
Schubert et al. “Efficacy of cannabinoids is a pre-clinical drug-screening platform for Alzheimer's disease” Mol Neurobiol; Nov. 2019 ePub May 2019; 56(11): 7719-7730.
[cited by applicant]
Scuteri et al. “NAbiximols clinical translation to the treatment of pain and agitation in severe dementia (NACTOPAISD): Clinical trial protocol” Biomed Pharmacother; Sep. 2022 ePub Aug. 2022; 153: 113488; doi: 10.1016/j…
[cited by applicant]
Shabbir et al. “Curcumin and its derivatives as theranostic agents in Alzheimer's disease: The implication of nanotechnology” Int J Mol Sci; Dec. 2020; 22(1): 196, doi: 10.3390/ijms22010196, 23 pages.
[cited by applicant]
Shahbazi et al. “Cannabinoids and cannabinoid receptors: The story so far” iScience; Jul. 2020; 23: 101301, doi: 0.1016/j.isci.2020.10130, 22 pages.
[cited by applicant]
Sharma & Kumar “Nature's derivative(s) as alternative anti-Alzheimer's disease treatments” J Alzheimers Dis Rep; Nov. 2019; 3(1): 279-297.
[cited by applicant]
Sharpe et al. “Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties” J Transl Med; Oct. 2020; 18(1): 374, doi: 10.1186/s12967-020-02518-2, 21 pages.
[cited by applicant]
Shelef et al. “Safety and efficacy of medical cannabis oil for behavioral and psychological symptoms of dementia: An-open label, add-on, pilot study” J Alzheimers Dis; Feb. 2016; 51(1): 15-19.
[cited by applicant]
Silvestro et al. “A state of the art of antioxidant properties of curcuminoids in neurodegenerative diseases” Int J Mol Sci; Mar. 2021; 22(6): 3168, doi: 10.3390/ijms22063168, 27 pages.
[cited by applicant]
Singer et al. “A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease” Sleep; Nov. 2003; 26(7): 893-901.
[cited by applicant]
Small et al. “Memory and brain amyloid and tau effects of a bioavailable form of curcumin in non-demented adults: A double-blind, placebo-controlled 18-month trial” Am J Geriatr Psychiatry; Mar. 2018; 26(3): 266-277.
[cited by applicant]
Solvay Pharmaceuticals, Inc. “Marinol (dronabinol) capsules” NDA 18-651/S-021; Sep. 2004; www.accessdata.fda.gov/drugsatfda_docs/label/2005/018651s021lbl.pdf, 11 pages.
[cited by applicant]
Srinivasan et al. “Melatonin in Alzheimer's disease and other neurodegenerative disorders” Behav Brain Funct; May 2006; 2: 15, doi: 10.1186/1744-9081-2-15, 23 pages.
[cited by applicant]
Stazi et al. “Long-term caffeine treatment of Alzheimer mouse models ameliorates behavioural deficits and neuron loss and promotes cellular and molecular markers of neurogenesis” Cell Mol Life Sci; Jan. 2022 ePub Dec. 2…
[cited by applicant]
Stazi et al. “A combination of caffeine supplementation and enriched environment in an Alzheimer's disease mouse model” Int J Mol Sci; Jan. 2023; 24(3): 2155, doi: 10.3390/ijms24032155, 15 pages.
[cited by applicant]
Stella et al. “Medical cannabinoids for treatment of neuropsychiatric symptoms in dementia: A systematic review” Trends Psychiatry Psychother; Jul. 2021; 43(4): 243-255.
[cited by applicant]
Stella et al. “Cannabinoid formulations and delivery systems: Current and future options to treat pain” Drugs; Sep. 2021; 81:(13) 1513-1557.
[cited by applicant]
Stout & Cimino “Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review” Drug Metab Rev; Feb. 2014; 46(1): 86-95.
[cited by applicant]
Sun et al. “Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer's disease” J Neuroinflammation; Jun. 2021; 18(1): 131, doi: 0.1186/s12974-021-02182-3, 14 pages.
[cited by applicant]
Svob Strac et al. “Personalizing the care and treatment of Alzheimer's disease: An overview” Pharmgenomics Pers Med; May 2021; 14: 631-653.
[cited by applicant]
IGC Pharma “IGC Pharma announces positive interim results for IGC-AD1 in reducing Alzheimer's agitation” IGC Pharma press release, Potomac, MD; Mar. 20, 2024; three pages.
[cited by applicant]
Charernboon et al. “Effectiveness of cannabinoids for treatment of dementia: A systematic review of randomized controlled trials” Clin Gerontol; Jan.-Feb. 2021; 44(1): 16-24.
[cited by applicant]
Cohen et al. “Study rationale and baseline data for pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's dementia (THC-AD)” Int Psychogeriatr; Oct. 2021; doi: 10.1017/S1041610221001150, six pages.
[cited by applicant]
Hoch et al. “How effective and safe is medical cannabis as a treatment of mental disorders? A systematic review” Eur Arch Psychiatry Clin Neurosci; Jan. 2019; 269(1): 87-105.
[cited by applicant]
Krishnan et al. “Cannabinoids for the treatment of dementia” Cochrane Database Syst Rev; Apr. 2009; 2009(2): CD007204, doi: 10.1002/14651858.CD007204.pub2, 21 pages.
[cited by applicant]
Paunescu et al. “A systematic review of clinical studies on the effect of psychoactive cannabinoids in psychiatric conditions in Alzheimer dementia” Am J Ther; May/Jun. 2020; 27(3): e249-e269.
[cited by applicant]
Ruthirakuhan et al. “Natural and synthetic cannabinoids for agitation and aggression in Alzheimer's disease: A meta-analysis” J Clin Psychiatry; Jan. 2019; 80(2): 18r12617, doi: 10.4088/JCP.18r12617, 13 pages.
[cited by applicant]
Tampi et al. “Cannabinoids for the treatment of behavioral and psychological symptoms of dementia” Neurodegener Dis Manag; Aug. 2018 ePub Jul. 2018; 8(4): 211-213, doi: 10.2217/nmt-2018-0019.
[cited by applicant]
Weier & Hall “The use of cannabinoids in treating dementia” Curr Neurol Neurosci Rep; Aug. 2017; 17(8): 56, doi: 10.1007/s11910-017-0766-6, nine pages.
[cited by applicant]
Defrancesco & Hofer “Cannabinoid as beneficial replacement therapy for psychotropics to treat neuropsychiatric symptoms in severe Alzheimer's dementia” Front Psychiatry; May 2020; 11: 413, doi: 10.3389/fpsyt.2020.00413,…
[cited by applicant]
DeMuro et al. “The absolute bioavailability of oral melatonin” J Clin Pharmacol; Jul. 2000; 40(7): 781-784.
[cited by applicant]
Devitt-Lee “Pot is hot—What you need to know” Sonoma Med; Oct. 2017; 68(4): 33-48.
[cited by applicant]
Devitt-Lee A Primer on Cannabinoid-Drug Interactions; Project CBD; Oct. 2018; 33 pages.
[cited by applicant]
Dragicevic et al. “Melatonin treatment restores mitochondrial function in Alzheimer's mice: A mitochondrial protective role of melatonin membrane receptor signaling” J Pineal Res; Aug. 2011 ePub Mar. 2011; 51(1): 75-86.
[cited by applicant]
Dragicevic et al. “Caffeine increases mitochondrial function and blocks melatonin signaling to mitochondria in Alzheimer's mice and cells” Neuropharmacology; Dec. 2012; 63(8): 1368-1379.
[cited by applicant]
Dubbelman et al. “Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum” Alzheimers Res Ther; Oct. 2020; 12(1): 138, doi: 10.1186/s13195-020-00706-2, 11 pages.
[cited by applicant]
Van den Elsen et al. “Tetrahydrocannabinol for neuropsychiatric symptoms in dementia” Neurology; Jun. 2015; 84(23): 2338-2346.
[cited by applicant]
Enogieru et al. “Rutin as a potent antioxidant: Implications for neurodegenerative disorders” Oxid Med Cell Longev; Jun. 2018; 2018: 6241017, doi: 10.1155/2018/6241017, 17 pages.
[cited by applicant]
Esposito et al. “The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells” J Mol Med (Berl); Mar. 2006; 84(3): 253-258.
[cited by applicant]
Esposito et al. “Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in 3-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-κB involvement” Neurosci Lett; May …
[cited by applicant]
Esposito et al. “Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression” Br J Pharmacol; Aug. 2007; 151(8): 1272-1279.
[cited by applicant]
Eubanks et al. “A molecular link between the active component of marijuana and Alzheimer's disease pathology” Mol Pharm; Nov.-Dec. 2006; 3(6): 773-777.
[cited by applicant]
Fasinu et al. “Current status and prospects for cannabidiol preparations as new therapeutic agents” Pharmacotherapy; Jul. 2016; 36(7): 781-796.
[cited by applicant]
Feng et al. “Melatonin alleviates behavioral deficits associated with apoptosis and cholinergic system dysfunction in the APP 695 transgenic mouse model of Alzheimer's disease” J Pineal Res; Sep. 2004; 37(2): 129-136.
[cited by applicant]
Fihurka et al. “The memory benefit to aged APP/PS1 mice from long-term intranasal treatment of low-cose THC” Int J Mol Sci; Apr. 2022; 23(8): 4253, doi: 10.3390/ijms23084253, 16 pages.
[cited by applicant]
Fishbein et al. “Long-term behavioral and biochemical effects of an ultra-low dose of Δ9-tetrahydrocannabinol (THC): Neuroprotection and ERK signaling” Exp Brain Res; Jul. 2012; 221(4): 437-448.
[cited by applicant]
Garcia-Mesa et al. “Melatonin plus physical exercise are highly neuroprotective in the 3xTg-AD mouse” Neurobiol Aging; Jun. 2012; 33(6): 1124e13-1124.e29, doi: 10.1016/j.neurobiolaging.2011.11.016, 37 pages.
[cited by applicant]
Giacoppo et al. “Cannabinoids: New promising agents in the treatment of neurological diseases” Molecules; Nov. 2014; 19(11): 18781-18816, doi: 10.3390/molecules191118781, 36 pages.
[cited by applicant]
Gonçalves et al. “Cannabis and its secondary metabolites: Their use as therapeutic drugs, toxicological aspects, and analytical determination” Medicines; Feb. 2019; 6(1): 31, doi: 10.3390/medicines6010031, 47 pages.
[cited by applicant]
Gonçalves et al. “Terpenoids, cannabimimetic ligands, beyond the Cannabis plant” Molecules; Mar. 2020; 25(7): 1567, doi: 10.3390/molecules25071567, 47 pages.
[cited by applicant]
Goozee et al. “Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease” Br J Nutr; Feb. 2016; 115(3): 449-465.
[cited by applicant]
Gorey et al. “Age-related differences in the impact of cannabis use on the brain and cognition: A systematic review” Eur Arch Psych Clin Neurosci; Feb. 2019; 269(1): 37-58.
[cited by applicant]
Graczyk et al. “Prospects for the use of cannabinoids in psychiatric disorders” Front Psychiatry; Mar. 2021; 12: 620073, doi: 10.3389/fpsyt.2021.620073, nine pages.
[cited by applicant]
Greenwich Biosciences, Inc. “Epidiolex (cannabidiol) oral solution prescribing information” Reference ID: 4282447; Jun. 2018; www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf, 30 pages.
[cited by applicant]
Gülck & Møller “Phytocannabinoids: Origins and biosynthesis” Trends Plant Sci; Oct. 2020 ePub Jul. 2020; 25(10): 985-1004.
[cited by applicant]
Habtemariam “Rutin as a natural therapy for Alzheimer's disease: Insights into its mechanisms of action” Curr Med Chem; Feb. 2016; 23(9): 860-873.
[cited by applicant]
Hardeland “Melatonin in aging and disease—Multiple consequences of reduced secretion, options and limits of treatment” Aging Dis; Apr. 2012; 3(2): 194-225.
[cited by applicant]
Hardeland “Divergent importance of chronobiological considerations in high- and low-dose melatonin therapies” Diseases; Mar. 2021; 9(1): 18, doi: 10.3390/diseases9010018, 16 pages.
[cited by applicant]
Hermann et al. “Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease” Am J Geriatr Psychiatry; Nov. 2019; 27(11): 1161-1173.
[cited by applicant]
Hillen et al. “Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: A systematic review” Ther Adv Drug Saf; May 2019; 10: 2042098619846993; doi: 10.1177/2042098619846993, …
[cited by applicant]
Huestis “Human cannabinoid pharmacokinetics” Chem Biodivers; Aug. 2007; 4(8): 1770-1804.
[cited by applicant]
Hunt & Jones “Tolerance and disposition of tetrahydrocannabinol in man” J Pharmacol Exp Ther; Nov. 1980; 215(1): 35-44.
[cited by applicant]
Iffland & Grotenhermen “An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies” Cannabis Cannabinoid Res; Jun. 2017; 2(1): 139-154.
[cited by applicant]
Insys Therapeutics, Inc. “Syndros (dronabinol) oral solution” Reference ID: 4103077; May 2017; www.accessdata.fda.gov/drugsatfda_docs/label/2017/205525s003lbl.pdf, 27 pages.
[cited by applicant]
Irwin “Healthy aging and dementia: Two roads diverging in midlife” Front Aging Neurosci; Sep. 2018; 10: 275, doi: 0.3389/fnagi.2018.0027, 12 pages.
[cited by applicant]
Jahromi et al. “Herbal medicine for pain management: Efficacy and drug interactions” Pharmaceutics; Feb. 2021; 13(2): 251, doi: 10.3390/pharmaceutics13020251, 30 pages.
[cited by applicant]
Jia et al. “Potential therapeutic strategies for Alzheimer's disease targeting or beyond β-amyloid: Insights from clinical trials” Biomed Res Int; Jul. 2014; 2014: 837157, doi: 10.1155/2014/837157, 22 pages.
[cited by applicant]
Thakur et al. “Natural cannabinoids: Templates for drug discovery” Life Sci; Dec. 2005 ePub Oct. 2005; 78(5): 454-466.
[cited by applicant]
Thakur et al. “Pathophysiology and management of Alzheimer's disease: An overview” J Anal Pharm Res; Apr. 2018; 7(2): 226-235.
[cited by applicant]
Timler et al. “Use of cannabinoid-based medicine among older residential care recipients diagnosed with dementia: Study protocol for a double-blind randomised crossover trial” Trials; Feb. 2020; 21(1): 188, doi: 10.1186…
[cited by applicant]
Uddin et al. “Emerging promise of cannabinoids for the management of pain and associated neuropathological alterations in Alzheimer's disease” Front Pharmacol; Jul. 2020; 11: 1097, doi: 10.3389/fphar.2020.01097, 13 page…
[cited by applicant]
Vacaflor et al. “Mental health and cognition in older cannabis users: A review” Can Geriatr J; Sep. 2020; 23(3): 242-249.
[cited by applicant]
Valeant Pharmaceuticals “Cesamet (nabilone) capsules” NDA 18-677/S-011; May 2006; www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf, 11 pages.
[cited by applicant]
Velayudhan et al. “Safety and tolerability of natural and synthetic cannabinoids in adults aged over 50 years: A systematic review and meta-analysis” PLoS Med; Mar. 2021; 18(3): e1003524, doi: 10.1371/journal.pmed.10035…
[cited by applicant]
Vergallo “Nutraceutical vegetable oil nanoformulations for prevention and management of diseases” Nanomaterials (Basel); Jun. 2020; 10(6): 1232, doi: 10.3390/nano10061232, 32 pages.
[cited by applicant]
Vitale et al. “The (poly)pharmacology of cannabidiol in neurological and neuropsychiatric disorders: Molecular mechanisms and targets” Int J Mol Sci; May 2021; 22(9): 4876, doi: 10.3390/ijms22094876, 20 pages.
[cited by applicant]
Volicer et al. “Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease” Int J Geriatr Psych; Sep. 1997; 12(9): 913-919.
[cited by applicant]
Wade et al. “Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: A 6-month, randomized, placebo-controlled, multicenter trial” Clin Interv Aging; Jun. 2014; 9: 94…
[cited by applicant]
Walther et al. “Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia” Psychopharmacology; May 2006 ePub Mar. 2006; 185(4): 524-528.
[cited by applicant]
Walther & Halpern “Cannabinoids and dementia: A review of clinical and preclinical data” Pharmaceuticals (Basel); Aug. 2010; 3(8): 2689-2708.
[cited by applicant]
Wang & Wang “Role of melatonin in Alzheimer-like neurodegeneration” Acta Pharmacol Sin; Jan. 2006; 27(1): 41-49.
[cited by applicant]
Wang et al. “Rutin inhibits β-amyloid aggregation and cytotoxicity, attenuates oxidative stress, and decreases the production of nitric oxide and proinflammatory cytokines” Neurotoxicology; Mar. 2012; 33(3): 482-490.
[cited by applicant]
Wang et al. “Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease—experimental approach and therapeutic implications” Front Aging Neurosci; Mar. 2014; 6: 42, doi: 10.3389/fn…
[cited by applicant]
Wang et al. “Low-dose delta-9-tetrahydrocannabinol as beneficial treatment for aged APP/PS1 mice” Int J Mol Sci; Mar. 2022; 23(5): 2757, doi: 10.3390/ijms23052757, 26 pages.
[cited by applicant]
Watt & Karl “In vivo evidence for therapeutic properties of cannabidiol (CBD) for Alzheimer's disease” Front Pharmacol; Feb. 2017; 8: 20, doi: 10.3389/fphar.2017.00020, seven pages.
[cited by applicant]
Xu et al. “Rutin improves spatial memory in Alzheimer's disease transgenic mice by reducing Aβ oligomer level and attenuating oxidative stress and neuroinflammation” Behav Brain Res; May 2014 ePub Feb. 2014; 264: 173-18…
[cited by applicant]
Zakaria et al. “The potential role of melatonin on memory function: Lessons from rodent studies” Folia Biol; May 2016; 62(5): 181-187.
[cited by applicant]
Zendulka et al. “Cannabinoids and cytochrome P450 interactions” Curr Drug Metab; 2016; 17(3): 206-226.
[cited by applicant]
Zeyl et al. “What do you know about Maryjane: A systematic review of the current data on the THC:CBD ratio” Subst Use Misuse; Mar. 2020; 55(8): 1223-1227.
[cited by applicant]
Zhornitsky & Potvin “Cannabidiol in humans—The quest for therapeutic targets” Pharmaceuticals (Basel); May 2012; 5(5): 529-552.
[cited by applicant]
Zuardi “History of cannabis as a medicine: A review” Rev Bras Psiquiatr; Jun. 2006;28(2): 153-157.
[cited by applicant]
Zuardi “Cannabidiol: From an inactive cannabinoid to a drug with wide spectrum of action” Rev Bras Psiquiatr; Sep. 2008; 30(3): 271-280.
[cited by applicant]
ISA/US “International Search Report” and “Written Opinion of the ISA” for parent Application No. PCT/US2019/000014 dated Jun. 14, 2019; 11 pages.
[cited by applicant]
WIPO “International Preliminary Report on Patentability” for parent Application No. PCT/US2019/000014 dated Oct. 6, 2020; seven pages.
[cited by applicant]
Laboratorio Franco Colombiano S.A.S.—Lafrancol S.A.S. “Opposition” dated Feb. 16, 2021 against corresponding Colombian Application No. NC2020/0013182 with English translation.
[cited by applicant]
Superintendencia de Industria y Comercio “Office Action No. 17586” dated Oct. 27, 2022 for corresponding Colombian Application No. NC2020/0013182 with partial English translation.
[cited by applicant]
European Patent Office “Supplementary European search report” & “European search opinion” dated May 10, 2022 for corresponding European Application No. 19777467.2, 12 pages.
[cited by applicant]
Instituto Mexicano de la Propiedad Industrial “First Office Action No. 72789” dated Aug. 10, 2022 for corresponding Mexican Application No. MX/a/2020/010284 with partial English translation.
[cited by applicant]
Instituto Mexicano de la Propiedad Industrial “Second Office Action No. 1686” dated Jan. 17, 2023 for corresponding Mexican Application No. MX/a/2020/010284 with partial English translation.
[cited by applicant]
US Patent and Trademark Office “Non-Final Office Action” dated May 2, 2022 for parent U.S. Appl. No. 17/042,333, 18 pages.
[cited by applicant]
US Patent and Trademark Office “Final Office Action” dated Nov. 14, 2022 for parent U.S. Appl. No. 17/042,333, 14 pages.
[cited by applicant]
Instituto Mexicano de la Propiedad Industrial “Third Office Action No. 49231” received Jun. 16, 2023 for corresponding Mexican Application No. MX/a/2020/010284 with partial English translation.
[cited by applicant]
IGC Pharma “IGC Pharma announces positive interim results for IGC-AD1 in reducing Alzheimer's agitation” shortened version From the Desk of the CEO, Potomac, MD; Mar. 20, 2024; two pages.
[cited by applicant]
IGC Pharma “IGC Pharma releases positive interim analysis of its ongoing Phase 2 trial in Alzheimer's research” From the Desk of the CEO, Potomac, MD; Apr. 5, 2024; three pages.
[cited by applicant]
IGC Pharma “IGC-AD1's interim Phase 2 data show a reduction in Alzheimer's agitation at week two” From the Desk of the CEO, Potomac, MD; Apr. 17, 2024; three pages.
[cited by applicant]
IGC Pharma “IGC Pharma announces positive interim results for IGC-AD1 in reducing Alzheimer's agitation in Its ongoing Phase 2 clinical trial” From the Desk of the CEO, Potomac, MD; Apr. 25, 2024; three pages.
[cited by applicant]
IGC Pharma “Recap of AAIC24 conference participation and poster presentations” From the Desk of the CEO, Potomac, MD; Aug. 28, 2024; nine pages.
[cited by applicant]
IGC Pharma “IGC Pharma advances IGC-AD1 toward clinical trials as a potential anti-amyloid plaque treatment for Alzheimer's disease” Press Release, Potomac, MD; Sep. 4, 2024; two pages.
[cited by applicant]
IGC Pharma “IGC Pharma announces additional data supporting IGC-AD1 as an Alzheimer's treatment” Press Release, Potomac, MD; Sep. 18, 2024; three pages.
[cited by applicant]
Bhoopatiraju & Grossberg “Emerging perspectives in the management of agitation in Alzheimer's disease and patients with dementia” touchREV Neurol; Jun. 2022; 18(1): 7-13.
[cited by applicant]
Caraci et al. “New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: Focus on brexpiprazole and pimavanserin” F1000Res; Jul. 2020 last updated Nov. 2024; 9(Faculty Rev): 686, doi: …
[cited by applicant]
Carrarini et al. “Agitation and dementia: Prevention and treatment strategies in acute and chronic conditions” Front Neurol; Apr. 2021; 12: 644317, doi: 10.3389/fneur.2021.644317, 18 pages.
[cited by applicant]
Cesana et al. “A confirmatory and an exploratory factor analysis of the Cohen-Mansfield Agitation Inventory (CMAI) in a European case series of patients with dementia: Results from the RECage Study” Brain Sci; Jul. 2023…
[cited by applicant]
Cohen-Mansfield “Instruction Manual for the Cohen-Mansfield Agitation Inventory (CMAI)” www.dementiaresearch.org.au/wp-content/uploads/2016/06/CMAI_Manual.pdf; 1991; 37 pages.
[cited by applicant]
Cohen-Mansfield “Agitated behavior in persons with dementia: The relationship between type of behavior, its frequency, and its disruptiveness” J Psychiatr Res; Nov. 2008; 43(1): 64-69, doi: 10.1016/j.jpsychires.2008.02.…
[cited by applicant]
Cummings et al. “Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition” Int Psychogeriatr; Jan. 2015 ePub Oct. 2014; 27(1): 7-17.
[cited by applicant]
Cummings et al. “Clinical trials for disease-modifying therapies in Alzheimer's disease: A primer, lessons learned, and a blueprint for the future” J Alzheimers Dis; Jan. 2018 ePub Mar. 2018; 64(suppl 1): S3-S22.
[cited by applicant]
Cummings et al. “Treatment combinations for Alzheimer's disease: Current and future pharmacotherapy options” J Alzheimers Dis; Jan. 2019; 67(3): 779-794.
[cited by applicant]
Cummings “Disease modification is not all—We need symptomatic therapies for Alzheimer disease” Nat Rev Neurol; Jan. 2022; 18(1): 3-4, doi: 10.1038/s41582-021-00591-9, three pages.
[cited by applicant]
Cummings et al. “Alzheimer's disease: Novel targets and investigational drugs for disease modification” Drugs; Oct. 2023 ePub Sep. 2023; 83(15): 1387-1408.
[cited by applicant]
Cummings et al. “The therapeutic landscape of tauopathies: Challenges and prospects” Alzheimers Res Ther; Oct. 2023; 15(1): 168, doi: 10.1186/s13195-023-01321-7, 17 pages.
[cited by applicant]
Dixon & Cadenhead “Cannabidiol versus placebo as adjunctive treatment in early psychosis: Study protocol for randomized controlled trial” Trials; Nov. 2023; 24(1): 775, doi: 10.1186/s13063-023-07789-w, 14 pages.
[cited by applicant]
Elmaleh et al. “Developing effective Alzheimer's disease therapies: Clinical experience and future directions” J Alzheimers Dis; Jan. 2019 ePub Aug. 2019; 71(3): 715-732.
[cited by applicant]
Hermush et al. “Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: A placebo controlled randomized clinical trial” Front Med; Sep. 2022; 9: 951889, doi: 10.3389/fmed.2022.951889, 14 pa…
[cited by applicant]
Imbido et al. “Emerging pharmacological approaches for psychosis and agitation in Alzheimer's disease” CNS Drugs; ePub Dec. 2024; doi: 0.1007/s40263-024-01133-9, 18 pages.
[cited by applicant]
Kim et al. “Alzheimer's disease: Key insights from two decades of clinical trial failures” J Alzheimers Dis; Jan. 2022 ePub Mar. 2022; 87(1): 83-100.
[cited by applicant]
Kupeli et al. “Psychometric evaluation of the Cohen-Mansfield Agitation Inventory in an acute general hospital setting” Int J Geriatr Psychiatry; Jan. 2018 ePub May 2017; 33(1): e158-e165, doi: 10.1002/gps.4741.
[cited by applicant]
Meunier et al. “Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer's dementia” Front Neurosci; Jul. 2024; 15: 1379062, doi: 10.3389/fneur.2024.13790…
[cited by applicant]
Omotayo et al. “A narrative review of the therapeutic and remedial prospects of cannabidiol with emphasis on neurological and neuropsychiatric disorders” J Cannabis Res; Mar. 2024; 6(1): 14, doi: 10.1186/s42238-024- 002…
[cited by applicant]
Park et al. “Emerging therapeutic opportunities for Alzheimer's disease psychosis” Preprints.org; Oct. 2024; doi: 10.20944/preprints202410.2470.v1, 16 pages.
[cited by applicant]
Pless et al. “Understanding neuropsychiatric symptoms in Alzheimer's disease: Challenges and advances in diagnosis and” Front Neurosci; Sep. 2023; 17: 1263771, doi: 10.3389/fnins.2023.1263771, 13 pages.
[cited by applicant]
Ride With Larry “Medical Marijuana and Parkinson's Part 3 of 3” YouTube; posted Nov. 2016; https://www.youtube.com/watch?v=zNT8Zo_sfwo from the documentary Ride With Larry, recorded in San Diego, CA(?); 2′ 33″ duration …
[cited by applicant]
Sano et al. “Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definition” Int Psychogeriatr; Apr. 2024 ePub Mar. 2023; 36(4): 238-250.
[cited by applicant]
Trojan et al. “The main therapeutic applications of cannabidiol (CBD) and its potential effects on aging with respect to Alzheimer's disease” Biomolecules; Sep. 2023; 13(10): 1446, doi: 10.3390/biom13101446, 13 pages.
[cited by applicant]
Thangwaritorn et al. “A review of recent advances in the management of Alzheimer's disease” Cureus; Apr. 2024; 16(4): e58416; doi: 10.7759/cureus.58416, 16 pages.
[cited by applicant]
Wise & Aga “Managing agitation in Alzheimer's disease: 5 things to know” Medscape; Jul. 2024; www.medscape.com/viewarticle/managing-agitation-alzheimers-disease-5-things-know-2024a1000caf?form=fpf; two pages.
[cited by applicant]
Yiannopoulou & Papageorgiou “Current and future treatments in Alzheimer disease: An update” J Cent Nerv Syst Dis; Feb. 2020; 12: 1179573520907397, doi: 10.1177/1179573520907397, 12 pages.
[cited by applicant]
Zhang et al. “Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies” Signal Transduct Target Ther; Aug. 2024; 9(1): 211, doi: 10.1038/s41392-024-01911-3, 35 pages.
[cited by applicant]
Zuidema et al. “Assessing neuropsychiatric symptoms in nursing home patients with dementia: Reliability and Reliable Index of the Neuropsychiatric Inventory and the Cohen-Mansfield Agitation Inventory” Int J Geriatr Psy…
[cited by applicant]